DZ Bank’s Cartesian Therapeutics RNAC Stock Holding History

DZ Bank’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-17,601	Closed	-$560K	–	1035
2023 Q3	$560K	Hold	17,601	–	–	﹤0.01%	711
2023 Q2	$591K	Hold	17,601	–	–	﹤0.01%	739
2023 Q1	$734K	Hold	17,601	–	–	﹤0.01%	711
2022 Q4	$597K	Hold	17,601	–	–	﹤0.01%	759
2022 Q3	$866K	Buy	+17,601	New	+$967K	﹤0.01%	705
2018 Q2	–	Sell	-1,338	Closed	-$409K	–	1048
2018 Q1	$409K	Buy	+1,338	New	+$381K	﹤0.01%	825

Other funds holding RNAC

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

DZ Bank's RNAC Position: Q4 2023 in Review

DZ Bank sold out of Cartesian Therapeutics (RNAC) in Q4 2023, closing a stake of 17,601 shares — an estimated $560K sold.

DZ Bank first reported a position in RNAC in Q1 2018 and held it in 6 quarters. The position peaked at $866K in Q3 2022. 80 funds tracked by Wall St. Rank hold RNAC as of Q4 2023.

DZ Bank reported no remaining Cartesian Therapeutics position as of Q4 2023 after selling out during the quarter.
DZ Bank sold 17,601 Cartesian Therapeutics shares in Q4 2023, an estimated $560K.
DZ Bank first reported a position in Cartesian Therapeutics in Q1 2018 and held it in 6 quarters.
DZ Bank's Cartesian Therapeutics position peaked at $866K in Q3 2022.
80 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2023.

Based on DZ Bank's 13F filing for Q4 2023, filed 14 Feb 2024.